Author name: Yali Friedman

The Health-Care Catastrophe That Won’t Happen Why biotech gains will rein in medical costs. The lesson of info tech

The Health-Care Catastrophe That Won’t Happen Why biotech gains will rein in medical costs. The lesson of info tech

Will U.S. try to circumvent drug firms patent? : The furor over Abbott Laboratories’ 400 percent price increase last December

Another gene genie out of the bottle The European Commission has lifted a five-year moratorium on genetically modified produce, by

Could patients glean stock tips?: Drug trial participants may be insider trading. “Patients in clinical trials might be using information

Financial Snapshot For March 2004: Looking Good “It’s been a rocky first quarter for the biotech stocks � and for

Full Steam Ahead “All told, biotech and specialty pharmas raised close to $6.4 billion in the first three months of

Money-Back Guarantee On Rx Drugs “Too many people with high blood pressure quit medication because they don’t feel bad –

Can the world afford to reject GM foods? “At a meeting in Brussels this week Dr Clive James, chair of

Are biotech jobs next to go? There are signs that the nation’s biotech industry may be on the verge of